# Lecture 03: Megaloblastic and Hemolytic Anemias ## Unit 2.9: Hematology and Oncology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the pathophysiology of megaloblastic anemia 2. Explain vitamin B12 and folate deficiency 3. Describe the classification of hemolytic anemias 4. Explain intrinsic RBC defects causing hemolysis 5. Describe extrinsic causes of hemolysis 6. Explain the diagnostic approach to hemolytic anemia --- ## Lecture Outline ### I. Megaloblastic Anemia Overview Megaloblastic anemia results from impaired DNA synthesis with relatively preserved RNA and protein synthesis, creating nuclear-cytoplasmic asynchrony where cytoplasmic maturation outpaces nuclear development. This fundamental defect affects all rapidly dividing cells throughout the body, though the effects are most apparent in hematopoietic tissue due to its high proliferative rate. The defining morphologic feature is the presence of megaloblasts, abnormally large erythroid precursors with immature-appearing nuclei containing fine reticular chromatin despite mature cytoplasm. Vitamin B12 and folate deficiency represent the most common causes, though certain drugs that interfere with DNA synthesis can produce identical findings. Laboratory findings in megaloblastic anemia reflect both the macrocytic red blood cells and the ineffective erythropoiesis characteristic of this condition. Mean corpuscular volume exceeds 100 femtoliters and often rises above 110 femtoliters in severe cases, producing some of the highest MCV values encountered clinically. The peripheral blood smear reveals macro-ovalocytes, which are enlarged oval red cells, along with hypersegmented neutrophils that serve as the earliest and most specific morphologic marker. Reticulocyte count is low relative to the degree of anemia, indicating hypoproliferative response. Lactate dehydrogenase is markedly elevated due to intramedullary destruction of megaloblastic precursors, a process termed ineffective erythropoiesis. Indirect bilirubin may be mildly elevated, and haptoglobin may decrease from the hemolysis component. Hypersegmented neutrophils provide an important diagnostic clue that often appears before anemia develops. Normal neutrophils have three to five nuclear lobes, whereas hypersegmented neutrophils display more than five lobes. The diagnostic threshold requires finding either a single neutrophil with six or more lobes or at least five percent of neutrophils with five lobes. This finding results from the same impaired DNA synthesis affecting granulocyte precursors and persists even after treatment begins, providing a useful retrospective clue when vitamin levels have normalized. Hypersegmented neutrophils are highly sensitive for megaloblastic anemia and should prompt evaluation for B12 and folate deficiency even in the absence of macrocytosis. Bone marrow examination in megaloblastic anemia reveals characteristic findings of ineffective erythropoiesis. Cellularity is increased, often strikingly hypercellular, as the marrow attempts to compensate for peripheral cytopenias. Erythroid precursors are enlarged with distinctive megaloblastic morphology showing immature nuclei with fine, lacy chromatin in cells with mature hemoglobinized cytoplasm. Giant metamyelocytes and band forms demonstrate similar nuclear-cytoplasmic asynchrony in the granulocytic lineage. Despite the hypercellular marrow, ineffective erythropoiesis causes intramedullary hemolysis with destruction of defective precursors before they can mature and enter circulation. This explains the paradox of pancytopenia with hypercellular marrow that characterizes severe megaloblastic anemia. Panel A: Peripheral blood smear showing hypersegmented neutrophil with six nuclear lobes adjacent to macro-ovalocytes. Panel B: Bone marrow aspirate demonstrating megaloblastic erythroid precursors with immature nuclei and giant metamyelocytes. Panel C: Diagram illustrating nuclear-cytoplasmic asynchrony with delayed nuclear maturation despite normal cytoplasmic development. Panel D: Comparison of normal erythroblast maturation versus megaloblastic maturation showing size and chromatin differences. --- ### II. Vitamin B12 (Cobalamin) Vitamin B12 metabolism involves a complex absorption pathway requiring multiple proteins and intact gastrointestinal function. Dietary sources include animal products such as meat, dairy, and eggs, with no significant plant sources making vegans dependent on supplements or fortified foods. In the stomach, acid and pepsin release B12 from food proteins, and it binds to R-protein secreted by salivary glands, which protects B12 from gastric degradation. In the duodenum, pancreatic proteases degrade R-protein, releasing B12 to bind intrinsic factor produced by gastric parietal cells. The intrinsic factor-B12 complex travels to the terminal ileum where it binds to the cubilin receptor for absorption. Transcobalamin II then carries B12 in plasma to tissues throughout the body. Vitamin B12 deficiency results from disruption at various points along this absorption pathway or, rarely, from inadequate dietary intake. Pernicious anemia represents the most important cause, involving autoimmune destruction of gastric parietal cells with resulting intrinsic factor deficiency and achlorhydria. Gastric causes also include gastrectomy, atrophic gastritis, and prolonged proton pump inhibitor use that impairs B12 release from food proteins. Ileal disease or resection, as in Crohn's disease affecting the terminal ileum, prevents absorption of the intrinsic factor-B12 complex. Bacterial overgrowth in blind loops consumes luminal B12 before absorption can occur. The fish tapeworm Diphyllobothrium latum competes for B12 in endemic areas. Strict vegan diet without supplementation causes deficiency slowly given the large hepatic B12 stores lasting three to five years. Pernicious anemia deserves special attention as the prototypical cause of B12 deficiency. This autoimmune condition produces antibodies against intrinsic factor, which are highly specific for pernicious anemia, and against parietal cells, which are more sensitive but less specific. Associated autoimmune conditions include vitiligo, autoimmune thyroid disease, and type 1 diabetes mellitus. The resulting achlorhydria creates an environment favoring bacterial overgrowth and further impairs B12 release from food. Patients with pernicious anemia have increased risk of gastric carcinoma and gastric carcinoid tumors, warranting consideration of endoscopic surveillance. The diagnosis is typically confirmed by demonstrating low B12 level with positive anti-intrinsic factor antibodies, though antibody-negative pernicious anemia does occur. Clinical features of B12 deficiency extend beyond hematologic manifestations to include distinctive neurologic and psychiatric findings. Hematologic features include megaloblastic anemia and pancytopenia from ineffective hematopoiesis. The neurologic hallmark is subacute combined degeneration affecting the posterior and lateral columns of the spinal cord, causing peripheral neuropathy, loss of vibration and position sense, ataxia, and spastic weakness. These neurologic manifestations may precede hematologic abnormalities and can occur with normal or near-normal hemoglobin levels. Psychiatric manifestations include dementia, depression, and psychosis, sometimes called "megaloblastic madness." Gastrointestinal findings include glossitis with a smooth, beefy red tongue and anorexia. Critically, folate supplementation can mask the hematologic manifestations while allowing neurologic damage to progress, making B12 assessment essential before treating macrocytic anemia. Panel A: Anatomic diagram showing B12 absorption pathway from stomach through terminal ileum with binding proteins at each step. Panel B: Illustration of pernicious anemia mechanism showing anti-intrinsic factor and anti-parietal cell antibodies blocking B12 absorption. Panel C: Cross-section of spinal cord demonstrating posterior and lateral column demyelination in subacute combined degeneration. Panel D: Clinical photograph of glossitis showing smooth, erythematous tongue typical of B12 deficiency. --- ### III. Folate Folate metabolism differs from B12 in its dietary sources, absorption site, and storage capacity, producing distinct clinical features despite similar hematologic presentations. Dietary folate is abundant in green leafy vegetables, fruits, fortified grains, and legumes. Absorption occurs primarily in the jejunum through carrier-mediated transport without the complex binding protein requirements of B12 absorption. Hepatic folate stores are limited to a three to four month supply, contrasting with the multi-year B12 reserves and explaining the more rapid onset of folate deficiency when intake becomes inadequate. Folate functions as a one-carbon carrier essential for thymidine and purine synthesis required for DNA replication, and notably, B12 is required to trap folate in its active intracellular form. Folate deficiency results from inadequate intake, malabsorption, or increased requirements that outstrip dietary supply. Dietary deficiency occurs with alcoholism through multiple mechanisms including poor intake, impaired absorption, and increased urinary losses. Elderly individuals with limited diets and those living in poverty are at risk. Malabsorptive conditions including celiac disease and tropical sprue impair jejunal folate uptake. Increased demand during pregnancy makes adequate folate essential, and deficiency during early gestation causes neural tube defects in the developing fetus. Chronic hemolytic anemias increase folate requirements due to accelerated erythropoiesis. Drugs interfering with folate metabolism include methotrexate, which inhibits dihydrofolate reductase, trimethoprim, and phenytoin, which impairs absorption. Clinical features of folate deficiency produce the same megaloblastic hematologic picture as B12 deficiency but lack the neurologic manifestations. The hematologic findings including macrocytic anemia, hypersegmented neutrophils, and pancytopenia are indistinguishable from B12 deficiency. The crucial distinguishing feature is the absence of neurologic involvement, as folate does not participate in myelin synthesis. This distinction has major therapeutic implications, as treating B12 deficiency with folate alone will improve the anemia while allowing irreversible neurologic damage to progress. Folate deficiency during pregnancy causes neural tube defects including spina bifida and anencephaly, leading to universal recommendations for folate supplementation in women of childbearing potential. Distinguishing B12 from folate deficiency requires specific laboratory testing beyond the similar hematologic findings. Serum B12 level is decreased in B12 deficiency and normal in isolated folate deficiency, though values may be borderline or affected by recent dietary intake. Serum folate decreases rapidly with dietary change and may not reflect tissue stores, while red blood cell folate provides a more reliable indicator of tissue status and is decreased in true folate deficiency. When B12 levels are borderline, metabolite levels help clarify the diagnosis. Methylmalonic acid is elevated specifically in B12 deficiency because B12 serves as a cofactor for methylmalonyl-CoA mutase. Homocysteine is elevated in both B12 and folate deficiency because both vitamins participate in the remethylation pathway converting homocysteine to methionine. Thus, elevated methylmalonic acid with elevated homocysteine indicates B12 deficiency, while normal methylmalonic acid with elevated homocysteine suggests folate deficiency. Panel A: Diagram showing folate absorption in the jejunum and its role in one-carbon transfer reactions for DNA synthesis. Panel B: Metabolic pathway illustrating the methyl trap hypothesis and interdependence of B12 and folate in homocysteine metabolism. Panel C: Comparison chart of B12 versus folate deficiency showing clinical and laboratory distinguishing features. Panel D: Illustration of neural tube defect development with folate deficiency during embryogenesis. --- ### IV. Diagnosis and Treatment of Megaloblastic Anemia The diagnostic approach to megaloblastic anemia follows a systematic sequence beginning with recognition of the characteristic findings and proceeding to specific vitamin level assessment. Initial confirmation requires demonstrating macrocytic anemia with MCV typically exceeding 100 femtoliters along with hypersegmented neutrophils on peripheral smear. Serum B12 and folate levels should be measured simultaneously, as mixed deficiencies occur and treatment of one deficiency may mask or worsen the other. When B12 level is borderline or low-normal and clinical suspicion remains high, methylmalonic acid and homocysteine levels help confirm deficiency. Once B12 deficiency is established, anti-intrinsic factor antibody testing identifies pernicious anemia as the underlying cause. Gastrointestinal evaluation with endoscopy may be indicated to identify other causes when the etiology remains unclear. Treatment of B12 deficiency traditionally employs parenteral administration to bypass the defective absorption that causes most cases. The standard intramuscular or subcutaneous regimen provides 1000 micrograms daily for seven days during the initial loading phase, followed by weekly injections for four weeks, then monthly maintenance injections indefinitely for pernicious anemia and other permanent causes. Remarkably, high-dose oral B12 at 1000 to 2000 micrograms daily can effectively treat even pernicious anemia through passive absorption independent of intrinsic factor, providing a convenient alternative for compliant patients. Neurologic symptoms should be treated urgently as damage may be only partially reversible, with earlier treatment producing better outcomes. Patients with pernicious anemia require lifelong B12 replacement regardless of the route of administration chosen. Treatment of folate deficiency involves oral replacement since absorption typically remains intact unless small bowel disease is responsible. Standard dosing provides 1 to 5 milligrams daily until deficiency is corrected and the underlying cause addressed. Before initiating folate therapy, B12 deficiency must be excluded or treated concurrently to prevent neurologic deterioration from treatment of folate deficiency alone. Prevention of neural tube defects requires folate supplementation of 400 micrograms daily for all women of childbearing potential, with higher doses of 4 milligrams daily for women with prior affected pregnancies. Fortification of grain products with folic acid has substantially reduced neural tube defect incidence since implementation in many countries. Response to appropriate therapy follows a predictable and gratifying timeline in uncomplicated megaloblastic anemia. Subjective improvement in well-being occurs within 24 to 48 hours of initiating therapy, even before measurable hematologic changes. Reticulocytosis appears within three to five days as the bone marrow responds to restored vitamin availability. Hemoglobin begins rising within one to two weeks and typically normalizes by six to eight weeks. Hypersegmented neutrophils may persist for one to two weeks after treatment initiation before resolving. Neurologic improvement following B12 replacement may continue for several months but is often incomplete when diagnosis was delayed, underscoring the importance of early recognition and treatment. Hypokalemia may develop during rapid erythropoietic response as potassium shifts into newly produced red cells, requiring monitoring in severe cases. Panel A: Diagnostic algorithm flowchart for megaloblastic anemia showing sequential testing from CBC through specific vitamin and metabolite levels. Panel B: Treatment timeline showing expected response milestones from symptoms through reticulocytosis to hemoglobin normalization. Panel C: Comparison of intramuscular versus oral B12 replacement regimens with indications for each approach. Panel D: Graph showing reticulocyte response curve following initiation of appropriate vitamin replacement therapy. --- ### V. Hemolytic Anemia Overview Hemolytic anemia results from shortened red blood cell survival below the normal 120-day lifespan, requiring increased marrow production to maintain red cell mass. When bone marrow compensatory capacity is adequate, hemolysis may produce reticulocytosis without anemia, termed compensated hemolysis. Decompensated hemolytic anemia occurs when destruction exceeds the marrow's maximum productive capacity of approximately six to eight times baseline. Classification distinguishes intrinsic hemolytic anemias caused by defects within the red blood cell, usually inherited, from extrinsic causes involving factors outside the cell attacking normal erythrocytes, typically acquired. Further classification separates inherited conditions from acquired disorders, helping predict chronicity and guide evaluation. Laboratory features of hemolysis reflect accelerated red cell destruction and the compensatory erythropoietic response. Reticulocyte count is elevated, typically exceeding 3 percent or 100,000 per microliter, representing the marrow's attempt to replace destroyed cells. Indirect bilirubin increases from heme catabolism exceeding hepatic conjugating capacity. Lactate dehydrogenase released from lysed red cells causes serum elevation. Haptoglobin, an alpha-2 globulin that binds free hemoglobin, decreases as it is consumed binding released hemoglobin and cleared by the reticuloendothelial system. The combination of elevated LDH and decreased haptoglobin is highly sensitive for hemolysis, with low haptoglobin being particularly useful as it rarely decreases from other causes. Urobilinogen in urine and stool increases from enhanced bilirubin metabolism. The distinction between intravascular and extravascular hemolysis has diagnostic and therapeutic implications. Intravascular hemolysis occurs when red cells are destroyed within the bloodstream, releasing free hemoglobin directly into plasma. Free hemoglobin exceeds haptoglobin binding capacity, resulting in hemoglobinemia, hemoglobinuria producing dark or red urine, and hemosiderinuria as renal tubular cells absorb hemoglobin and later shed iron-laden debris. Haptoglobin is very low or undetectable. Examples include transfusion reactions, paroxysmal nocturnal hemoglobinuria, and severe microangiopathic hemolysis. Extravascular hemolysis involves red cell destruction by macrophages in the spleen and liver without free plasma hemoglobin. Haptoglobin is low but not as profoundly depleted. Hereditary spherocytosis and warm autoimmune hemolytic anemia exemplify extravascular hemolysis. Peripheral blood smear examination provides crucial morphologic clues to the cause of hemolysis. Spherocytes, small dense red cells lacking central pallor, suggest hereditary spherocytosis or warm autoimmune hemolytic anemia. Schistocytes, fragmented red cells with sharp angles and helmet shapes, indicate microangiopathic hemolytic anemia from thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, disseminated intravascular coagulation, or mechanical heart valves. Sickle cells identify sickle cell disease. Target cells appear in hemoglobinopathies, liver disease, and post-splenectomy states. Bite cells, appearing as if a bite was taken from the cell, result from Heinz body removal by splenic macrophages and suggest oxidant injury in G6PD deficiency. Recognizing these morphologic patterns often suggests the diagnosis before confirmatory testing. Panel A: Diagram comparing intravascular versus extravascular hemolysis showing sites of red cell destruction, hemoglobin fate, and resulting laboratory findings. Panel B: Laboratory profile comparison showing typical values for LDH, bilirubin, haptoglobin, and reticulocytes in hemolytic versus non-hemolytic anemia. Panel C: Gallery of peripheral blood smear findings in hemolysis including spherocytes, schistocytes, sickle cells, and bite cells with diagnostic associations. Panel D: Schematic of hemoglobin processing by haptoglobin and subsequent hepatic clearance. --- ### VI. Membrane Defects Hereditary spherocytosis represents the most common inherited red cell membrane disorder, caused by defects in proteins linking the lipid bilayer to the underlying cytoskeleton. Mutations affect spectrin, ankyrin, band 3, or protein 4.2, with autosomal dominant inheritance accounting for approximately 75 percent of cases. The weakened membrane-cytoskeleton interactions cause progressive membrane loss as red cells traverse the spleen, transforming normal biconcave discs into spheres with reduced surface area to volume ratio. These spherocytes are poorly deformable and become trapped in the splenic cords where they undergo premature destruction by macrophages. The resulting extravascular hemolysis produces chronic anemia of variable severity depending on the specific mutation and residual protein function. Clinical features of hereditary spherocytosis reflect chronic hemolysis and its complications. Anemia severity varies from fully compensated hemolysis without anemia to severe transfusion-dependent disease, with most patients experiencing mild to moderate anemia. Unconjugated hyperbilirubinemia from chronic hemolysis causes jaundice and promotes formation of pigmented gallstones, often presenting in adolescence or early adulthood. Splenomegaly develops from chronic trapping and destruction of abnormal red cells. Aplastic crises from parvovirus B19 infection cause acute severe anemia when the virus temporarily suppresses erythropoiesis, eliminating the compensatory reticulocytosis that maintains hemoglobin. Megaloblastic crises from folate deficiency may occur when chronically increased folate demand is not met. Diagnosis of hereditary spherocytosis relies on clinical features, characteristic laboratory findings, and specific confirmatory testing. Peripheral blood smear shows spherocytes lacking central pallor alongside polychromatophilic reticulocytes. Mean corpuscular hemoglobin concentration is often elevated above 36 grams per deciliter because spherocytes are dehydrated with relatively more hemoglobin per unit volume. Osmotic fragility testing demonstrates increased lysis in hypotonic saline solutions that cause normal cells to swell before lysing. Eosin-5-maleimide binding assay by flow cytometry shows reduced fluorescence due to decreased band 3, providing excellent sensitivity and specificity. Direct antiglobulin test is negative, distinguishing hereditary spherocytosis from autoimmune hemolytic anemia, which also produces spherocytes. Treatment of hereditary spherocytosis addresses symptomatic disease and prevents complications. Folic acid supplementation at 1 milligram daily supports increased erythropoietic requirements in all patients with ongoing hemolysis. Splenectomy eliminates the site of red cell destruction and typically cures or substantially improves the anemia, though spherocytosis persists and membrane fragility remains unchanged. Indications for splenectomy include moderate to severe disease with symptomatic anemia, growth delay in children, or significant complications. Pre-splenectomy vaccination against encapsulated organisms including pneumococcus, meningococcus, and Haemophilus influenzae is essential given post-splenectomy infection risk. Partial splenectomy may preserve some splenic function while reducing hemolysis in selected pediatric patients. Cholecystectomy may be combined with splenectomy when symptomatic gallstones are present. Panel A: Diagram of red cell membrane showing spectrin-actin cytoskeleton and vertical linkages to integral membrane proteins affected in hereditary spherocytosis. Panel B: Peripheral blood smear comparison showing normal biconcave red cells alongside spherocytes lacking central pallor. Panel C: Osmotic fragility curve demonstrating increased hemolysis of spherocytes at higher saline concentrations compared to normal cells. Panel D: Clinical photograph showing scleral icterus and jaundice in a patient with hereditary spherocytosis. --- ### VII. Enzyme Defects Glucose-6-phosphate dehydrogenase deficiency is the most common human enzyme deficiency, affecting over 400 million people worldwide with highest prevalence in Africa, the Mediterranean, and Asia. G6PD catalyzes the first step of the hexose monophosphate shunt, generating NADPH that maintains glutathione in its reduced form to protect against oxidative damage. X-linked inheritance causes hemizygous males to be fully affected while heterozygous females show variable expression depending on random X-inactivation patterns. The geographic distribution reflects selection pressure from malaria, as G6PD deficiency provides relative protection against Plasmodium falciparum infection. Multiple variants exist with different degrees of enzyme deficiency, with the A-minus variant common in Africa producing mild disease and Mediterranean variants causing more severe deficiency. Clinical manifestations of G6PD deficiency vary from asymptomatic carrier status to severe hemolytic crises triggered by oxidant stress. At baseline, most affected individuals have normal hemoglobin with adequate G6PD activity in young red cells. Oxidant stress from infections, certain drugs, or fava bean ingestion overwhelms the limited antioxidant capacity, causing acute hemolytic episodes. Oxidant drugs to avoid include antimalarials such as primaquine, sulfonamides, dapsone, and nitrofurantoin. Fava beans, also called broad beans, contain oxidant compounds causing favism in susceptible individuals, particularly those with Mediterranean variants. Acute hemolysis typically begins one to three days after exposure, with dark urine from hemoglobinuria, jaundice, and falling hemoglobin. The severity of Mediterranean variants produces more dramatic crises than the A-minus variant. Diagnosis of G6PD deficiency requires awareness of timing issues that can cause false-negative results during acute hemolysis. Peripheral blood smear during acute episodes shows bite cells where Heinz bodies have been pitted out by splenic macrophages, along with blister cells and irregular contracted cells. Heinz bodies, representing denatured hemoglobin precipitates, require supravital staining with crystal violet for visualization and are not seen on routine Wright-stained smears. Quantitative G6PD enzyme assay confirms the diagnosis but may be falsely normal during acute hemolysis because older, more deficient cells have been destroyed and reticulocytes have higher enzyme activity. Testing should be repeated two to three months after an acute episode when the red cell population has normalized. Genetic testing can identify specific variants. Treatment of G6PD deficiency centers on preventing hemolytic crises through oxidant avoidance and providing supportive care during acute episodes. Patient education about drugs and foods to avoid is essential, ideally provided with a written list of prohibited medications. Screening before prescribing oxidant drugs in high-risk populations prevents iatrogenic hemolysis. During acute hemolytic crises, treatment is supportive with hydration to maintain renal function in the face of hemoglobinuria, and transfusion for severe symptomatic anemia. Folic acid supplementation may be provided during recovery. Acute episodes are self-limited as the remaining younger red cells have adequate enzyme activity, and hemoglobin typically recovers within one to two weeks unless the oxidant exposure continues. Chronic hemolysis occurs only in severe variants with very low baseline enzyme activity. Panel A: Biochemical pathway diagram showing G6PD role in the hexose monophosphate shunt generating NADPH to maintain reduced glutathione. Panel B: Peripheral blood smear showing bite cells and blister cells during acute G6PD deficiency crisis. Panel C: Heinz body preparation with supravital crystal violet staining showing inclusions of denatured hemoglobin. Panel D: World map showing geographic distribution of G6PD deficiency prevalence correlating with historical malaria endemicity. --- ### VIII. Immune Hemolytic Anemia Immune hemolytic anemias result from antibodies binding to red blood cell surface antigens and mediating their destruction through complement activation, phagocytosis, or both. Classification distinguishes warm autoimmune hemolytic anemia caused by IgG antibodies reactive at body temperature from cold autoimmune hemolytic anemia caused by IgM antibodies reactive at lower temperatures. Drug-induced immune hemolysis occurs through several distinct mechanisms. Alloimmune hemolysis results from antibodies against foreign red cell antigens as in transfusion reactions or hemolytic disease of the newborn. The direct antiglobulin test, also called the Coombs test, demonstrates antibody or complement coating the red cell surface and is essential for diagnosis. Warm autoimmune hemolytic anemia involves IgG antibodies that bind red cells optimally at 37 degrees Celsius, coating the cells and targeting them for destruction by splenic macrophages. Hemolysis is predominantly extravascular as antibody-coated cells are recognized and phagocytosed by Fc receptor-bearing macrophages in the spleen. The direct antiglobulin test is positive for IgG with or without C3 complement. Approximately half of cases are idiopathic while secondary causes include chronic lymphocytic leukemia, systemic lupus erythematosus, other autoimmune diseases, and drugs. Treatment follows a stepwise approach beginning with corticosteroids as first-line therapy, followed by rituximab for steroid-refractory cases, and splenectomy for those failing initial therapies. Transfusion may be necessary for life-threatening anemia despite the challenge of finding compatible blood. Cold agglutinin disease involves IgM antibodies that bind red cells at temperatures below body temperature, activating complement and causing agglutination. As blood circulates through cool peripheral extremities, IgM binds red cells and fixes complement. When cells return to warmer central circulation, IgM dissociates but complement remains, leading to extravascular destruction of C3-coated cells in the liver and some intravascular hemolysis from complement completion. The direct antiglobulin test is positive for C3 only, with IgG typically negative. Causes include idiopathic chronic cold agglutinin disease, post-infectious syndromes following Mycoplasma pneumoniae or Epstein-Barr virus, and underlying lymphoproliferative disorders. Symptoms include hemolytic anemia plus acrocyanosis and Raynaud-like symptoms in cold-exposed extremities from red cell agglutination. Treatment emphasizes cold avoidance, with rituximab for symptomatic chronic cases and complement inhibitors such as sutimlimab representing newer options. The direct antiglobulin test is the cornerstone diagnostic test for immune hemolytic anemia, detecting antibodies or complement bound to red cell surfaces. Polyspecific reagent contains anti-IgG and anti-C3, with positive results followed by monospecific testing to determine which component is present. IgG positivity alone or with C3 indicates warm autoimmune hemolytic anemia. C3 positivity alone suggests cold agglutinin disease or drug-induced complement-mediated hemolysis. Both IgG and C3 may occur in mixed-type autoimmune hemolysis or certain drug reactions. Negative direct antiglobulin test effectively excludes immune hemolytic anemia and redirects evaluation toward intrinsic red cell defects or non-immune extrinsic causes. False negatives may rarely occur with low-affinity antibodies or when antibodies have eluted off cells. Panel A: Mechanism diagram comparing warm autoimmune hemolytic anemia with IgG-mediated splenic sequestration versus cold agglutinin disease with complement-mediated destruction. Panel B: Direct antiglobulin test schematic showing anti-human globulin bridging antibody or complement on red cell surfaces to cause visible agglutination. Panel C: Clinical photograph showing acrocyanosis of fingertips in cold agglutinin disease from peripheral red cell agglutination. Panel D: Algorithm for interpreting direct antiglobulin test results with diagnostic associations for different patterns. --- ### IX. Microangiopathic Hemolytic Anemia (MAHA) Microangiopathic hemolytic anemia results from mechanical fragmentation of red blood cells as they traverse abnormal microvasculature, producing the characteristic schistocytes on peripheral blood smear. The hemolysis is intravascular as cells are physically sheared within blood vessels, producing hemoglobinemia, hemoglobinuria, and markedly decreased haptoglobin. The direct antiglobulin test is negative because no antibodies are involved in the destruction mechanism. Thrombocytopenia commonly accompanies MAHA because platelet-fibrin thrombi in the microvasculature cause both the mechanical hemolysis and platelet consumption. Recognition of schistocytes should prompt urgent evaluation for underlying thrombotic microangiopathies and other causes. Thrombotic thrombocytopenic purpura represents a life-threatening thrombotic microangiopathy requiring emergent treatment. The classic pentad of microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, renal dysfunction, and fever is seen in full in only a minority of cases, and the diagnosis should be considered with any combination of MAHA and thrombocytopenia. The underlying pathophysiology involves deficiency of ADAMTS13, a metalloprotease that cleaves ultra-large von Willebrand factor multimers. Without ADAMTS13 activity, these large multimers cause spontaneous platelet aggregation and microvascular thrombosis. Acquired TTP results from inhibitory autoantibodies against ADAMTS13, while congenital TTP stems from inherited ADAMTS13 mutations. Diagnosis is supported by ADAMTS13 activity below 10 percent. Treatment requires urgent plasma exchange to remove antibodies and replenish ADAMTS13, along with corticosteroids and caplacizumab, an anti-von Willebrand factor agent. Hemolytic uremic syndrome shares the MAHA-thrombocytopenia presentation with TTP but is distinguished by prominent acute kidney injury. Typical or STEC-HUS follows infection with Shiga toxin-producing Escherichia coli, most commonly the O157:H7 serotype, causing bloody diarrhea followed by the classic triad of MAHA, thrombocytopenia, and acute kidney injury. This form predominantly affects children and treatment is supportive, as antibiotics may increase toxin release and worsen outcomes. Atypical HUS results from inherited or acquired complement dysregulation causing uncontrolled complement activation on endothelial surfaces. Unlike STEC-HUS, atypical HUS lacks the diarrheal prodrome and tends to recur. Treatment with eculizumab or ravulizumab, complement C5 inhibitors, has dramatically improved outcomes in atypical HUS. Other causes of microangiopathic hemolytic anemia include disseminated intravascular coagulation, mechanical heart valves, and severe hypertension. DIC produces consumption coagulopathy with prolonged prothrombin time and activated partial thromboplastin time, elevated D-dimer, and decreased fibrinogen, distinguishing it from TTP and HUS where coagulation tests are typically normal. Prosthetic heart valves, particularly mechanical valves with paravalvular leaks, cause chronic low-grade MAHA from turbulent flow shearing red cells. Malignant hypertension with blood pressures exceeding 180/120 mmHg causes fibrinoid necrosis of arterioles with resulting microangiopathy. HELLP syndrome occurring in pregnancy combines hemolysis, elevated liver enzymes, and low platelets, requiring delivery for definitive treatment. Cancer-associated microangiopathy, particularly with mucin-secreting adenocarcinomas, produces MAHA through tumor-related microvascular changes. Panel A: Peripheral blood smear demonstrating schistocytes including helmet cells, triangular fragments, and microspherocytes characteristic of microangiopathic hemolysis. Panel B: Pathophysiology diagram of TTP showing deficient ADAMTS13 activity allowing ultra-large von Willebrand factor multimers to cause platelet aggregation. Panel C: Comparison of TTP, HUS, and DIC showing overlapping and distinguishing features including renal involvement, coagulation parameters, and ADAMTS13 activity. Panel D: Kidney biopsy histology from HUS showing thrombotic microangiopathy with glomerular capillary thrombi. --- ### X. Other Causes of Hemolysis Infections can cause hemolysis through various mechanisms depending on the causative organism. Malaria represents the most significant infectious cause of hemolysis worldwide, with Plasmodium species invading and replicating within red blood cells, ultimately causing cell rupture during schizont release. Babesiosis, caused by the intraerythrocytic parasite Babesia, produces a similar picture and should be considered in endemic areas. Clostridium perfringens produces lecithinase that directly lyses red cell membranes, causing massive intravascular hemolysis as a complication of gas gangrene or septic abortion. Mycoplasma pneumoniae infection may trigger cold agglutinin production causing autoimmune hemolysis. Severe bacterial infections can cause oxidant damage to red cells, particularly in G6PD-deficient individuals whose antioxidant defenses are compromised. Drug-induced hemolysis occurs through several distinct mechanisms requiring different diagnostic and management approaches. Hapten-mediated hemolysis occurs when drugs such as high-dose penicillin bind to the red cell surface, creating a neoantigen against which antibodies form. Immune complex formation occurs when drug-antibody complexes deposit on red cells and activate complement, as described with quinidine. Autoantibody induction occurs when drugs trigger formation of true autoantibodies reactive against red cell antigens in the drug's absence, as seen with methyldopa and fludarabine. Direct oxidant injury occurs when drugs cause oxidative damage to hemoglobin and membrane lipids, particularly affecting G6PD-deficient individuals. Treatment for all drug-induced hemolysis begins with discontinuing the offending agent, with supportive care as the hemolysis resolves. Hypersplenism causes hemolysis through sequestration and destruction of red cells in an enlarged spleen. The spleen normally filters approximately 5 percent of circulating red cells, removing damaged or antibody-coated cells. Splenomegaly from any cause, including portal hypertension with cirrhosis, myeloproliferative neoplasms, or infiltrative diseases, increases this filtration and destruction, producing mild hemolytic anemia. Thrombocytopenia and neutropenia commonly accompany the anemia as platelets and neutrophils are also sequestered. The peripheral smear may show target cells, and the bone marrow demonstrates appropriate hyperplasia in response to increased peripheral destruction. Treatment addresses the underlying cause of splenomegaly when possible. Transfusion reactions represent a critical cause of hemolysis that must be recognized and managed promptly. Acute hemolytic transfusion reactions result from ABO incompatibility, typically due to clerical errors, causing rapid intravascular hemolysis with complement activation. Symptoms include fever, chills, flank pain, dyspnea, hypotension, and dark urine from hemoglobinuria. Complications include disseminated intravascular coagulation, acute kidney injury, and shock. Immediate management requires stopping the transfusion, maintaining intravenous access, aggressive fluid resuscitation, and supportive care for DIC and renal failure. Delayed hemolytic transfusion reactions occur three to fourteen days after transfusion when an anamnestic antibody response destroys transfused cells, presenting with falling hemoglobin, fever, and jaundice. Recognition allows supportive care and ensures future transfusions avoid the implicated antigen. Panel A: Blood smear showing ring forms of Plasmodium falciparum within infected red blood cells demonstrating malaria parasitemia. Panel B: Diagram illustrating different mechanisms of drug-induced hemolysis including hapten, immune complex, and autoantibody pathways. Panel C: Splenomegaly on CT scan with caption noting the causes and consequences of hypersplenism. Panel D: Flowchart for management of acute hemolytic transfusion reaction from recognition through supportive care. --- ## Summary - Megaloblastic anemia results from impaired DNA synthesis causing nuclear-cytoplasmic asynchrony, macrocytosis often exceeding MCV of 110 fL, and hypersegmented neutrophils on peripheral smear - Vitamin B12 deficiency causes neurologic damage including subacute combined degeneration that may be irreversible, occurring with or without hematologic manifestations - Pernicious anemia is the prototypical cause of B12 deficiency involving autoimmune destruction of parietal cells and intrinsic factor deficiency - Folate deficiency produces identical hematologic findings but lacks neurologic involvement and may mask B12 deficiency if treated alone - Hemolytic anemia features elevated reticulocytes, increased LDH and indirect bilirubin, and decreased haptoglobin, with intravascular hemolysis additionally showing hemoglobinemia and hemoglobinuria - Hereditary spherocytosis is the most common membrane defect, producing spherocytes, extravascular hemolysis, and response to splenectomy - G6PD deficiency causes episodic hemolysis triggered by oxidant stress, with bite cells and Heinz bodies during acute episodes - Warm AIHA involves IgG antibodies and positive DAT, treated with steroids, rituximab, and splenectomy - MAHA produces schistocytes and accompanies TTP, HUS, and DIC, requiring urgent differentiation and specific treatment --- ## Key Terms | Term | Definition | |------|------------| | Megaloblast | Abnormally large erythroid precursor with immature nucleus and mature cytoplasm due to impaired DNA synthesis | | Hypersegmented neutrophil | Neutrophil with more than five nuclear lobes, the earliest sign of megaloblastic anemia | | Subacute combined degeneration | Demyelination of posterior and lateral spinal cord columns from B12 deficiency causing sensory ataxia and weakness | | Spherocyte | Red blood cell lacking central pallor due to membrane loss, seen in hereditary spherocytosis and autoimmune hemolysis | | Schistocyte | Fragmented red blood cell indicating microangiopathic hemolytic anemia | | DAT (Direct Antiglobulin Test) | Coombs test detecting antibodies or complement on red cell surfaces in immune hemolytic anemia | | Haptoglobin | Alpha-2 globulin that binds free hemoglobin, decreased in hemolysis | | MAHA | Microangiopathic hemolytic anemia from mechanical red cell fragmentation in abnormal microvasculature | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*